• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 8, Issue 3
  3. Authors

Online ISSN: 2515-8260

Volume8, Issue3

Fractalkine (CX3CL1) as a Diagnostic Marker for Childhood Onset Systemic Lupus Erythematosus

    Alshymaa A. Ahmed Ebtehag H. Hassan Hany Elsayed Asmaa M. Alhussiny

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 2453-2463

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: - more specific, sensitive, and in the same time non-invasive indicators for the early prediction of juvenile SLE are required.
Aim: - to evaluate serum fractalkine (CX3CL1) as a diagnostic marker, predictor of nephritis, and indicator of disease activity in pediatric SLE.
Methods: - study included 41 children newly diagnosed with SLE, age ranged from 5 to 18 years, 24 (58.5%) were presented lupus nephritis “diagnosed by renal biopsy”. A total of 20 healthy age and sex matched children were included as controls. Serum Fractalkine levels were measured using human CX3CL1 ELISA.
Results: - Serum Fractalkine were significantly higher in SLE patients (median = 1323, range 591- 16547 IU/ml) than healthy controls (median = 950, range 591- 1583 u/ml) p=0.001. Serum Fkn can be a significant diagnostic marker for juvenile lupus indicated by the are under the ROC curve, AUC = 0.81 (95% confidence interval [CI], 0.70-0.92, P<0.001), at the level 1213 IU/ml serum Fkn detected SLE with sensitivity 0.78 (95% CI, 0.62 - 0.89), specificity 0.91 (95% CI, 0.71 – 0.99), positive predictive value 0.94 (95% CI, 0.80 – 0.98), negative predictive value 0.67 (95% CI, 0.55- 0.80), and accuracy 0.82 (95% CI, 0.71 – 0.91). Serum levels of Fkn showed no statistically significant differences when compared in patients with lupus nephritis against patients without nephritis, and was not correlated with disease activity.
Conclusions: - Serum level of Fractalkine can be a diagnostic marker for childhood onset SLE either with or without lupus nephritis, with no significant correlation with activity status or the stage of LN.
Keywords:
    Biomarkers CX3CL1 Fractalkine pediatric lupus nephritis Systemic lupus erythematosus
  • PDF (298 K)
  • XML
(2021). Fractalkine (CX3CL1) as a Diagnostic Marker for Childhood Onset Systemic Lupus Erythematosus. European Journal of Molecular & Clinical Medicine, 8(3), 2453-2463.
Alshymaa A. Ahmed; Ebtehag H. Hassan; Hany Elsayed; Asmaa M. Alhussiny. "Fractalkine (CX3CL1) as a Diagnostic Marker for Childhood Onset Systemic Lupus Erythematosus". European Journal of Molecular & Clinical Medicine, 8, 3, 2021, 2453-2463.
(2021). 'Fractalkine (CX3CL1) as a Diagnostic Marker for Childhood Onset Systemic Lupus Erythematosus', European Journal of Molecular & Clinical Medicine, 8(3), pp. 2453-2463.
Fractalkine (CX3CL1) as a Diagnostic Marker for Childhood Onset Systemic Lupus Erythematosus. European Journal of Molecular & Clinical Medicine, 2021; 8(3): 2453-2463.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 234
  • PDF Download: 333
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus